Advertisement
Advertisement


Press Release

FDA Approves New Oral Powder Formulation of Ritonavir (Norvir, RTV)

June 8, 2017

On June 7, 2017, the Food and Drug Administration approved a new Norvir (ritonavir) oral powder formulation, 100 mg packet. This approval provides for the use of Norvir (ritonavir) oral powder (only for >100 mg dose increments) in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. Norvir oral powder dosage form is free of alcohol and propylene glycol, both of which are present in the currently marketed Norvir oral solution, making it safer for use in the pediatric population.

Additionally, labeling was revised for the Norvir tablet for oral use and oral solution to reflect the new powder formulation.

The complete revised labeling will be available soon at Drugs@FDA and at DailyMed.

Norvir is manufactured by AbbVie Inc.




Visit the FDA's website to find out more about their activities and publications.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.